Ro4-1539: Difference between revisions

Browse history interactively ← Previous edit Next edit →Content deleted Content addedVisual WikitextInline

Revision as of 16:40, 12 September 2011 editPotatoBot (talk \| contribs)Bots51,239 editsm Stub sorting and placement of stub template(s): analgesic-stub. See approval. Report errors and suggestions at User talk:PotatoBot.← Previous edit		Revision as of 13:40, 23 October 2011 edit undo70.137.143.167 (talk) cite patentNext edit →
Line 39:		Line 39:
	}}		}}

	'''Ro4-1539''' ('''Furethylnorlevorphanol''') is an ] ] drug from the ] series, which was developed by the pharmaceutical company ] in the 1950s.<ref>US ~~Patent~~ 2970147</ref> It acts as a potent ] agonist, and was found to be around 30-60x more potent than the related drug ] in animal experiments.<ref></ref><ref>Hellerbach J, Schnider O, Besendorf H, Pellmont B. Synthetic Analgesics. Part IIA. Morphinans. Pergamon Press, 1966.</ref> While it is notable for its high potency, being among the more potent μ-agonist found in the morphinan series of drugs (though not on the scale of ] and other morphinans in the extremity of their level of potency), Ro4-1539 had no particular clinical advantages over other available opioid drugs, and was never commercially marketed.		'''Ro4-1539''' ('''Furethylnorlevorphanol''') is an ] ] drug from the ] series, which was developed by the pharmaceutical company ] in the 1950s.<ref>{{cite patent \| US \| 2970147 }}</ref> It acts as a potent ] agonist, and was found to be around 30-60x more potent than the related drug ] in animal experiments.<ref></ref><ref>Hellerbach J, Schnider O, Besendorf H, Pellmont B. Synthetic Analgesics. Part IIA. Morphinans. Pergamon Press, 1966.</ref> While it is notable for its high potency, being among the more potent μ-agonist found in the morphinan series of drugs (though not on the scale of ] and other morphinans in the extremity of their level of potency), Ro4-1539 had no particular clinical advantages over other available opioid drugs, and was never commercially marketed.

	Ro4-1539 has never been formally trialled in humans, but based on its effects in animals it would be expected to produce effects similar to those of other potent opioid agonists, including strong ], ], ], ], ] and also ] which could be harmful or fatal.		Ro4-1539 has never been formally trialled in humans, but based on its effects in animals it would be expected to produce effects similar to those of other potent opioid agonists, including strong ], ], ], ], ] and also ] which could be harmful or fatal.



	==See also==		==See also==

Revision as of 13:40, 23 October 2011

Pharmaceutical compound

Ro4-1539
Identifiers

IUPAC name 17-(2-(furan-2-yl)ethyl)-3-hydroxymorphinan
CAS Number	27767-85-7
PubChem CID	20834001
CompTox Dashboard (EPA)	DTXSID20950452
Chemical and physical data
Formula	C₂₂H₂₇NO₂
Molar mass	337.454 g/mol g·mol
3D model (JSmol)	Interactive image
SMILES C3CCCC1C35c2cc(O)ccc2CC1N(CC5)CCc4ccco4
(verify)

Ro4-1539 (Furethylnorlevorphanol) is an opioid analgesic drug from the morphinan series, which was developed by the pharmaceutical company Hoffmann–La Roche in the 1950s. It acts as a potent μ-opioid agonist, and was found to be around 30-60x more potent than the related drug levorphanol in animal experiments. While it is notable for its high potency, being among the more potent μ-agonist found in the morphinan series of drugs (though not on the scale of acetorphine and other morphinans in the extremity of their level of potency), Ro4-1539 had no particular clinical advantages over other available opioid drugs, and was never commercially marketed.

Ro4-1539 has never been formally trialled in humans, but based on its effects in animals it would be expected to produce effects similar to those of other potent opioid agonists, including strong analgesia, sedation, euphoria, constipation, itching and also respiratory depression which could be harmful or fatal.